Laura C Pinheiro1, Devon K Check2, Donald Rosenstein3, Katherine E Reeder-Hayes3, Stacie Dusetzina4. 1. Division of General Internal Medicine, Department of Medicine, Weill Cornell Medicine, 525 East 68th Street, Box 331, New York, NY, 10065, USA. lcp2003@med.cornell.edu. 2. Duke University, Durham, NC, USA. 3. University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 4. Vanderbilt University, Nashville, TN, USA.
Abstract
BACKGROUND: Compared to non-Hispanic Whites, Hispanic women are more likely to report pain, depression, and other mental health concerns. However, little is known about Hispanic women's use of supportive medications, and whether use differs depending on nativity (US- vs. foreign-born). This study's objectives were to examine patterns of supportive medication use and investigate potential differences by ethnicity/nativity among women with breast cancer. METHODS: We used the Surveillance, Epidemiology, and End Results data linked with Medicare claims to identify women diagnosed with incident breast cancer between July 1, 2007, and December 31, 2011. Supportive medication use (opioid pain and non-opioid psychotropic medications) in the 90 days after diagnosis was the primary outcome. We categorized ethnicity/nativity as US-Born non-Hispanic, US-born Hispanic, foreign-born non-Hispanic, and foreign-born Hispanic. Modified Poisson models examined associations between ethnicity/nativity and medication use, adjusting for tumor, treatment, and demographic characteristics. RESULTS: We included 23,091 women, of whom 88% were US-born non-Hispanics, 4% US-born Hispanics, 6% foreign-born non-Hispanics, and 2% foreign-born Hispanics. Supportive medication use varied by ethnicity/nativity. Compared to US-born non-Hispanics, foreign-born Hispanics and non-Hispanics were 5% (95% CI 0.92-0.98) and 10% (95% CI 0.85-0.96) less likely to receive supportive medications, respectively. US-born Hispanics were 5% (95% CI 1.02-1.09) more likely to receive supportive medications. Observed differences persisted when analyses were limited to stage I-III breast cancer cases. CONCLUSIONS: This work highlights potential disparities in the pharmacologic treatment of psychosocial needs of foreign-born breast cancer patients. Future studies should explore if differences observed here are reflective of health disparities or differential patient preferences.
BACKGROUND: Compared to non-Hispanic Whites, Hispanic women are more likely to report pain, depression, and other mental health concerns. However, little is known about Hispanic women's use of supportive medications, and whether use differs depending on nativity (US- vs. foreign-born). This study's objectives were to examine patterns of supportive medication use and investigate potential differences by ethnicity/nativity among women with breast cancer. METHODS: We used the Surveillance, Epidemiology, and End Results data linked with Medicare claims to identify women diagnosed with incident breast cancer between July 1, 2007, and December 31, 2011. Supportive medication use (opioid pain and non-opioid psychotropic medications) in the 90 days after diagnosis was the primary outcome. We categorized ethnicity/nativity as US-Born non-Hispanic, US-born Hispanic, foreign-born non-Hispanic, and foreign-born Hispanic. Modified Poisson models examined associations between ethnicity/nativity and medication use, adjusting for tumor, treatment, and demographic characteristics. RESULTS: We included 23,091 women, of whom 88% were US-born non-Hispanics, 4% US-born Hispanics, 6% foreign-born non-Hispanics, and 2% foreign-born Hispanics. Supportive medication use varied by ethnicity/nativity. Compared to US-born non-Hispanics, foreign-born Hispanics and non-Hispanics were 5% (95% CI 0.92-0.98) and 10% (95% CI 0.85-0.96) less likely to receive supportive medications, respectively. US-born Hispanics were 5% (95% CI 1.02-1.09) more likely to receive supportive medications. Observed differences persisted when analyses were limited to stage I-III breast cancer cases. CONCLUSIONS: This work highlights potential disparities in the pharmacologic treatment of psychosocial needs of foreign-born breast cancerpatients. Future studies should explore if differences observed here are reflective of health disparities or differential patient preferences.
Entities:
Keywords:
Breast cancer; Disparities; Hispanic; Latina; Supportive care
Authors: Tim Luckett; David Goldstein; Phyllis N Butow; Val Gebski; Lynley J Aldridge; Joshua McGrane; Weng Ng; Madeleine T King Journal: Lancet Oncol Date: 2011-10-11 Impact factor: 41.316
Authors: Victoria Blinder; Sujata Patil; Carolyn Eberle; Jennifer Griggs; Rose C Maly Journal: Breast Cancer Res Treat Date: 2013-07-25 Impact factor: 4.872
Authors: Ayse Akincigil; Mark Olfson; Michele Siegel; Karen A Zurlo; James T Walkup; Stephen Crystal Journal: Am J Public Health Date: 2011-12-15 Impact factor: 9.308
Authors: Betty R Ferrell; Jennifer S Temel; Sarah Temin; Erin R Alesi; Tracy A Balboni; Ethan M Basch; Janice I Firn; Judith A Paice; Jeffrey M Peppercorn; Tanyanika Phillips; Ellen L Stovall; Camilla Zimmermann; Thomas J Smith Journal: J Clin Oncol Date: 2016-10-28 Impact factor: 44.544
Authors: Nayan Lamba; Elie Mehanna; Rachel B Kearney; Paul J Catalano; Daphne A Haas-Kogan; Brian M Alexander; Daniel N Cagney; Kathleen A Lee; Ayal A Aizer Journal: Neuro Oncol Date: 2020-09-29 Impact factor: 12.300
Authors: Gemma Clarke; Emma Chapman; Jodie Crooks; Jonathan Koffman; Shenaz Ahmed; Michael I Bennett Journal: BMC Palliat Care Date: 2022-04-06 Impact factor: 3.234